Apr 17, 2023
American Association for Cancer Research (AACR) 2023: A next generation TEAD inhibitor with refined isoform specificity for superior safety & efficacy
View PresentationDeveloping targeted cancer treatments requires an in depth understanding of cancer biology, its genetic vulnerabilities, and its symbiotic interactions within the tumor microenvironment. Our team of renowned cancer biologists and expert drug developers is applying its knowledge base across these fields to develop new therapeutic candidates that address cancer with the full picture in mind.
View the latest news and press releases from Sporos Bioventures
View all newsApr 17, 2023
American Association for Cancer Research (AACR) 2023: A next generation TEAD inhibitor with refined isoform specificity for superior safety & efficacy
View PresentationApr 17, 2023
Sporos BioDiscovery Presents Preclinical Data on Next-Generation TEAD Inhibitor, SPR1-0117, at the American Association for Cancer Research (AACR) Annual Meeting 2023
SPR1-0117 is a novel isoform-selective inhibitor of TEAD1 / TEAD4 Preclinical data show inhibition of…
READ MOREMar 15, 2023
Sporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2023
HOUSTON, Texas., March 15, 2023 — Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos…
READ MORE